Bill Text: NJ A276 | 2020-2021 | Regular Session | Introduced
Bill Title: Prohibits pharmaceutical manufacturer from owning or operating drug rehabilitation facility licensed in State.
Spectrum: Partisan Bill (Democrat 4-0)
Status: (Introduced - Dead) 2020-01-14 - Introduced, Referred to Assembly Human Services Committee [A276 Detail]
Download: New_Jersey-2020-A276-Introduced.html
STATE OF NEW JERSEY
219th LEGISLATURE
PRE-FILED FOR INTRODUCTION IN THE 2020 SESSION
Sponsored by:
Assemblyman JOHN ARMATO
District 2 (Atlantic)
Assemblyman VINCENT MAZZEO
District 2 (Atlantic)
Assemblywoman CAROL A. MURPHY
District 7 (Burlington)
Co-Sponsored by:
Assemblyman Mukherji
SYNOPSIS
Prohibits pharmaceutical manufacturer from owning or operating drug rehabilitation facility licensed in State.
CURRENT VERSION OF TEXT
Introduced Pending Technical Review by Legislative Counsel.
An Act concerning drug rehabilitation facilities and supplementing Title 26 of the Revised Statutes.
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
1. The Division of Mental Health and Addiction Services in the Department of Human Services shall not grant or renew the license of a facility that provides treatment or other services to individuals with a substance use disorder if the facility is owned or operated, wholly, partially, directly, indirectly, or in any manner, by a manufacturer of pharmaceutical products.
2. Pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), the Department of Human Services may adopt rules and regulations necessary to effectuate the provisions of this act.
3. This act shall take effect 180 days after the date of enactment.
STATEMENT
This bill prohibits a pharmaceutical manufacturer from owning or operating a drug rehabilitation facility licensed in this State. Under the bill, the Division of Mental Health and Addiction Services in the Department of Human Services is not to grant or renew the license of a facility that provides treatment or other services to individuals with a substance use disorder if the facility is owned or operated, wholly, partially, directly, indirectly, or in any manner, by a manufacturer of pharmaceutical products.
